We get leadership teams from scattered AI experiments to working workflows in weeks. Training, platform setup, and hands-on builds across pharma, biotech, and professional services.
Your team already uses AI. Mostly on personal accounts, mostly in secret, mostly without guardrails. Every casual prompt with client data in it is a risk nobody signed off on.
Meanwhile the official rollout sits in compliance review. The security questions are fair. But while they wait for answers, the shadow use grows.
This is a leadership challenge. And it can be handled in weeks, with the right sequence.
A phased path from first workshop to documented, repeatable workflows. Start small, decide at every step.
A private space to ask the questions you can't ask in front of your team, and leave with language you can use on Monday.
Built from pre-workshop interviews with your team. Everyone leaves with at least one working prompt or assistant.
Anonymous readiness survey, management readout, then a live build of 1 or 2 prototypes with your team.
The strongest prototype becomes a documented workflow with quality checks and human-in-the-loop points.
Monthly or bi-weekly sessions. What's relevant, what's noise, and what's coming next for your industry.

A career inside pharma: commercial, market access, and cross-functional projects across Italy, Germany, and Denmark. He knows the regulatory sensitivities and what it takes to change how scientific teams work.

6 companies over 20 years in the US, UK, and Denmark, each one built on technology that changed what was possible. Now working with founders and CEOs on the organizational change new tools force.
Two free ways to find out where you actually stand before we ever get on a call.
The 5 strategic decisions that determine whether you build capability or just buy tools.
Get the guide7 minutes, anonymous, and you'll know exactly where your organization stands.
Take the assessmentThe two-track approach that keeps momentum while the security questions get real answers.
The objection patterns are the same everywhere. Here's what actually shifts them.
The decision framework we use with biotech and medcom clients, in the open.